MADIA

Magnetic Diagnostic

Assay for

Neurodegenerative Diseases

  • Altzheimer s Disease
  • MADIA slideshow
  • Pathological Cascade

MADIA will develop a versatile and cost-effective in-vitro tool for early diagnosis of Alzheimer’s and Parkinson’s diseases. Alzheimer’s and Parkinson’s diseases, the two most common neurodegenerative disorder worldwide, are debilitating and largely untreatable conditions that are strongly linked with age.

Alzheimer’s is the most common form of dementia, affecting seven million across Europe. The global cost of dementia in 2015 was around US$ 820 billion, meaning that age-related neurodegenerative disease is one of the largest medical and societal challenges faced by our society.

Costs of dementia in 2015 (billion US$), by G7 and G20 country classification

Costs of dementia in 2015 (billion US$), by G7 and G20 country classification


(Source: World Alzheimer Report 2015 - The Global Impact of Dementia: An analysis of prevalence, incidence, cost and trends.)
The MADIA technology

The MADIA technology

MADIA aims at fabricating devices based on arrays of magnetic sensors integrated into a microfluidics device and capable of recognising biomarkers, obtained from cerebrospinal fluid or blood samples, conjugated with ultra-small magnetic nanoparticles.


This will allow the early diagnosis of Alzheimer’s and Parkinson’s diseases and improve the efficacy of current therapies which have been shown to slow the progression, particularly of Parkinson’s disease, as currently there is no cure for either disease.

Read more

THIS WEBSITE STORES AND GAIN ACCESS TO INFORMATION ALREADY STORED IN USER’S DEVICE BY THE USAGE OF COOKIES. CONSENT OR LACK OF CONSENT FOR THE USAGE OF COOKIES MAY BY EXPRESSED BY A BROWSER CONFIGURATION